Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Vemurafenib (Primary)
- Indications Thyroid cancer
- Focus Pharmacodynamics; Therapeutic Use
- 17 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 22 Feb 2017 Status changed from active, no longer recruiting to recruiting.